Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 7;41(39):5678-5682.
doi: 10.1016/j.vaccine.2023.08.023. Epub 2023 Aug 19.

Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines

Tat'Yana A Kenigsberg  1 , Kristin Goddard  2 , Kayla E Hanson  3 , Ned Lewis  2 , Nicola Klein  2 , Stephanie A Irving  4 , Allison L Naleway  4 , Bradley Crane  4 , Tia L Kauffman  4 , Stanley Xu  5 , Matthew F Daley  6 , Laura P Hurley  7 , Robyn Kaiser  8 , Lisa A Jackson  9 , Amelia Jazwa  1 , Eric S Weintraub  10
Affiliations

Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines

Tat'Yana A Kenigsberg et al. Vaccine. .

Abstract

The U.S. Food and Drug Administration authorized use of mRNA COVID-19 bivalent booster vaccines on August 31, 2022. Currently, CDC's clinical guidance states that COVID-19 and other vaccines may be administered simultaneously. At time of authorization and recommendations, limited data existed describing simultaneous administration of COVID-19 bivalent booster and other vaccines. We describe simultaneous influenza and mRNA COVID-19 bivalent booster vaccine administration between August 31-December 31, 2022, among persons aged ≥6 months in the Vaccine Safety Datalink (VSD) by COVID-19 bivalent booster vaccine type, influenza vaccine type, age group, sex, and race and ethnicity. Of 2,301,876 persons who received a COVID-19 bivalent booster vaccine, 737,992 (32.1%) received simultaneous influenza vaccine, majority were female (53.1%), aged ≥18 years (91.4%), and non-Hispanic White (55.7%). These findings can inform future VSD studies on simultaneous influenza and COVID-19 bivalent booster vaccine safety and coverage, which may have implications for immunization service delivery.

Keywords: Co-administration; Seasonal influenza vaccine; Simultaneous vaccination; mRNA covid-19 bivalent booster vaccine.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kayla E. Hanson reports financial support was provided by Seqirus Srl. Nicola P. Klein reports financial support was provided by Pfizer. Nicola P. Klein reports financial support was provided by Sanofi Pasteur Inc. Nicola P. Klein reports financial support was provided by Merck & Co Inc. Nicola P. Klein reports financial support was provided by GlaxoSmithKline Inc. Allison L. Naleway reports financial support was provided by Pfizer. Allison L. Naleway reports financial support was provided by Vir Biotechnology Inc. Lisa A. Jackson reports financial support was provided by Pfizer.

Similar articles

See all similar articles

Cited by

References

    1. Food and Drug Administration. Pfizer-BioNTech COVID-19 vaccine letter of authorization (reissued). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/media/150386/download.
    1. Food and Drug Administration. Moderna COVID-19 vaccine letter of authorization (reissued). Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2022. https://www.fda.gov/media/144636/download.
    1. Centers for Disease Control and Prevention. CDC Expands Updated COVID-19 Vaccines to Include Children Ages 6 Months through 5 Years [Press release]; 2022, December 9. https://www.cdc.gov/media/releases/2022/s1209-covid-vaccine.html.
    1. Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States. US Department of Health and Human Services, CDC; 2022. Accessed February 17, 2023, from https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-co....
    1. Kenigsberg TA, Hanson KE, Klein NP, Zerbo O, Goddard K, Xu S, et al. Safety of simultaneous vaccination with COVID-19 vaccines in the Vaccine Safety Datalink. Vaccine 2023;41:4658–65. 10.1016/j.vaccine.2023.06.042. - DOI - PMC - PubMed

Publication types

LinkOut - more resources